Skip to content

Role of Marichyadi Syrup and Marichyadi Lozenges in the management of cough.

A double arm open label comparative clinical trial on Marichyadi Syrup and Marichyadi Lozenges dosage forms for managing Kasa with special reference Acute Bronchitis in children. - Nil

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/101453
Enrollment
60
Registered
2026-01-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J069- Acute upper respiratory infection,unspecified

Interventions

None listed

Sponsors

State Ayurvedic college and hospital Lucknow
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects irrespective of gender, religion, socioeconomic status and between the age group of 6-15 years. 2. Acute kasa from day 1 to 3 weeks with or without presence of mucus will be enrolled. 3. Mild fever (37.5 degree celcius to 38.5 degree celcius or 99.5 degree fahrenheit to 101.4 degree fahrenheit should will be enrolled.

Exclusion criteria

Exclusion criteria: 1. Patient below age of 6 years and above 15 years should be excluded from the study. 2. High grade fever above 38.5 degree celcius or 101.4 degree fahrenheit should be excluded. 3. Patient having Kasa as upadrava or anubandha lakshana (complication) of other systemic disease. 4. Patient suffering from any severe disease of lower respiratory tract infection. Any chronic illness disease of respiratory system eg. TB, Chronic lung disease, Bronchiectasis, Pleurisy which is known. 5. Serious cardiovascular, cerebrovascular, renal and liver disease or severe illness. Patient suffering from any systemic disorder( like Diabetes Mellitus). 6. Children with any congenital abnormality. 7. During course of treatment if the subject develops any acute illness requiring acute managem ent, such patients will be excluded out of the study and continued with conventional treatment. 8. Patients/parents who are not willing to continue the treatment.

Design outcomes

Primary

MeasureTime frame
Improvement in the symptoms of the children after 14 days of the trial.Timepoint: After completing 14 days of the clinical trial.

Secondary

MeasureTime frame
Access the efficacy of trial medicine and Improvement in all the symptoms and quality of life of children in 21 days of trial.Timepoint: After completing 21 days of the clinical trial.

Countries

India

Contacts

Public ContactDr Mahesh Narayan Gupta

State Ayurvedic college and hospital Lucknow

mngupta75@yahoo.com9415447523

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026